FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  SANDAGE BOBBY W PHD
 2. Date of Event Requiring Statement (Month/Day/Year)
09/13/2011		 3. Issuer Name and Ticker or Trading Symbol
CORONADO BIOSCIENCES INC [NONE]
(Last)
(First)
(Middle)
C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President and CEO
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

BURLINGTON, MA 01803		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Options to purchase Common Stock   (1) 04/14/2021 Common Stock 300,000 $ 1.93 D  
Series C Convertible Preferred Stock 05/26/2011   (2) Common Stock 10,000 $ 5.59 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
SANDAGE BOBBY W PHD
C/O CORONADO BIOSCIENCES, INC.
15 NEW ENGLAND EXECUTIVE PARK
BURLINGTON, MA 01803		   X     President and CEO  

Signatures

By: Bobby W. Sandage, Jr. 09/13/2011
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) One-third of the shares will vest on each of April 14, 2012, 2013 and 2014.
(2) Each share of Series C Convertible Preferred Stock shall be automatically converted into shares of Common Stock based on the then-effective conversion price immediately prior to the declaration or ordering of effectiveness of a resale registration filed by the issuer registering for resale by the holders thereof all of the Common Stock issuable upon conversion of the shares of Series C Convertible Preferred Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.